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Background: International policy towards access to essential medicines in Africa has focused until recently on
international procurement of large volumes of medicines, mainly from Indian manufacturers, and their import and
distribution. This emphasis is now being challenged by renewed policy interest in the potential benefits of local
pharmaceutical production and supply. However, there is a shortage of evidence on the role of locally produced
medicines in African markets, and on potential benefits of local production for access to medicines. This article
contributes to filling that gap.
Methods: This article uses WHO/HAI data from Tanzania for 2006 and 2009 on prices and sources of a set of tracer
essential medicines. It employs innovative graphical methods of analysis alongside conventional statistical testing.
Results: Medicines produced in Tanzania were equally likely to be found in rural and in urban areas. Imported
medicines, especially those imported from countries other than Kenya (mainly from India) displayed ‘urban bias’:
that is, they were significantly more likely to be available in urban than in rural areas. This finding holds across the
range of sample medicines studied, and cannot be explained by price differences alone. While different private
distribution networks for essential medicines may provide part of the explanation, this cannot explain why the
urban bias in availability of imported medicines is also found in the public sector.
Conclusions: The findings suggest that enhanced local production may improve rural access to medicines. The
potential benefits of local production and scope for their improvement are an important field for further research,
and indicate a key policy area in which economic development and health care objectives may reinforce each
other.
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This article contributes new analysis and findings to the
debate concerning the scope for local pharmaceutical
manufacturing in Africa to provide benefits to the popu-
lation in terms of improved access to medicines. Using
existing data sets, it presents empirical evidence of
‘urban bias’ in the distribution of imported essential
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unless otherwise stated.in Tanzania are equally likely to be found in rural and
urban outlets, imported medicines – especially those
manufactured outside the region – are less likely to be
available in rural areas. Since rural areas contain a dis-
proportionate share of extreme poverty in Tanzania,
these are findings of real concern for health policy. The
article explores possible explanations of these observa-
tions, and identifies policy implications concerning the
potential benefits of linking of health and industrial pol-
icy by African policy makers, and potential health bene-
fits were donors to pay greater attention to sourcing
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Over the last decade, there has been a huge increase in
international funding for access to essential medicines,
with a particular focus on HIV, TB and malaria in
Sub-Saharan Africa [1-4]. Large scale international pro-
curement of medicines is sourced predominantly from
Indian manufacturers [5-7], a procurement strategy jus-
tified by international policy makers on grounds of lower
prices and improved quality control. Many international
analysts remain critical of the scope for locally produced
medicines to improve access to medicines in African
contexts [8-10].
However, there is increasing policy interest, among
African and international policy makers, researchers,
and some donors and suppliers, in the scope for im-
proved local African pharmaceutical supply and its
potential benefits [11]. The World Health Organization
(WHO) is leading a project on the topic funded by
the European Union in collaboration with UNCTAD
[12-14]. There is currently substantial international sup-
port from UNIDO and from some aid agencies, notably
GIZ, for strengthening local pharmaceutical production
in Africa [15-17]. The African Union has been leading
on the development of a Pharmaceutical Plan for Africa,
supported by UNIDO and working with NEPAD and
COHRED [18,19]. There is active policy development by
a number of African governments, including Ghana,
Uganda and South Africa, and involving pharmaceutical
manufacturers’ associations such as SAGMA [16,20,21].
Donors and international NGOs, including PEPFAR and
Action Medeor, have been developing local pharmaceut-
ical procurement in a number of Africa countriesa.
There remains however limited evidence to date of the
nature and extent of benefits of local production in
terms of medicines access [10].
Methods and theory
Methods
The main sources of the findings presented in this article
are the WHO/HAI medicines surveys conducted each
year in Tanzania during 2006-2009b. The data used here
are from the 2006 and 2009 surveys. The data collection,
following WHO/HAI guidelines for the surveys at that
time [22] included both price data and data on manufac-
turer and country of origin of each of 40 tracer medi-
cines covered in both the 2006 and 2009 surveysc. A
total of 96 facilities in public and faith-based sectors and
private shops, in four regions of Tanzania, were included
in both surveysd. Sample sizes used to calculate probabil-
ities in this article are: for 2006, rural, 40 medicines × 47
outlets = 1880 observations; urban, 40 medicines × 46
outlets = 1840 observations; for 2009, rural, 40 medicines
× 47 outlets = 1880 observations; urban: 40 medicines
× 45 outlets = 1800 observations. The manufacturer andcountry of origin data from the two surveys were coded
and analysed, and the article also uses the price data in
the findings and discussion. Prices per dose were calcu-
lated using Tanzanian standard treatment guidelines for
dosages [23].
In addition, this article also draws on field data col-
lected during 2006-7, as part of a research project on
the role of non-governmental public action in medicines
accesse, and on interviewing for an unpublished report
to UNITAIDf.
The data were analysed using Stata for quantitative
analysis and NVivo for qualitative data. A specific fea-
ture of this article is that it combines conventional stat-
istical two-sample tests for proportions with the use of
innovative graphical methods to display and explore the
extent of urban bias over the range of medicines. These
graphical methods avoid the loss of information result-
ing from averaging data across medicines, displaying re-
sults for each medicine in a parsimonious manner. The
basic rationale for adopting this method is that ‘there is
no single statistical tool that is as powerful as a well-
chosen graph’ [24]. More specifically, the curvatures of
patterns (including the location of unusual data points)
that can easily be detected in a visual display are often
rendered obscure or less easy to judge from an equiva-
lent table of the data [24] p.1. This is particularly the
case when the analysis requires looking at patterns
across a range of 40 medicines.
Theory
The analytical framework for the discussion of our re-
sults in this paper draws both on economic analysis of
health and medicines markets, and on the ‘urban bias’
literature in development studies. The concept of ‘urban
bias’ [25] has a contested but still productive role in de-
velopment theory and policy [26-28]. The concept char-
acterises processes that are biased against rural areas in
a manner that undermines both economic efficiency and
equity. We are concerned in this article not with price
‘twists’ [25], nor centrally with ‘public-expenditure urban
bias’ [27] p.229 though the latter may be part of the pol-
icy story, but rather we draw on the more general con-
cept of ‘distributional urban bias’ [26]. This descriptive
use of ‘urban bias’ is found in some of the health and
development literature with reference to inequity in the
distribution of public provision and NGO activity in
healthg. We analyse here the extent to which distribution
mechanisms for imported medicines – but not for lo-
cally produced medicines – appear systematically to dis-
favour the rural population.
Since the rural areas in Tanzania include the majority of
the households in severe poverty in the country [29],
urban bias in essential medicines availability is of policy
concern. Recognising the high levels of commercialisation
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we explore in this article the extent to which our findings
on urban bias in imported medicines distribution may be
explained by lesser purchasing power in rural areas. We
also use qualitative evidence and evidence from other
studies to consider the role of consumer and clinician
preferences in the outcomes, as well as the organisation of
public and private wholesaling.
Results
This section presents systematically the findings from
the WHO/HAI survey data for 2006. Given the innova-
tive graphical method of analysis, we do not present in
the text the comparable graphs for 2009, in order to pre-
vent ‘graph overload’ in the exposition. We comment on
and assess at each stage in the text the similarities and
differences between the 2006 and 2009 survey findings,
and we present the statistical test results for the two
years, to confirm that the 2006 findings are not unique
to that year. We also make available the 2009 compara-
tive figures in a web-based appendix [Additional file 1]
for readers interested in confirmation and further detail.
Urban bias in access to essential medicines
Measured by on-the-shelves availability on a given day,
in health facilities and shops, access to medicines in
Tanzania is systematically worse in rural than urban
areas [35,36]h. Figure 1 presents the evidence on avail-
ability from the 2006 survey, in a graphical format that
avoids presentation of averages across medicines. The
figure charts the probability, for each tracer medicine, of
its availability in a sample facility or shop, in a rural orFigure 1 Probability of finding each medicine in rural and urban samin an urban area, on the day of the 2006 survey. The
data points are thus the proportion of the facilities and
shops, in urban and rural areas respectively, that stocked
the medicine on the survey day. The medicines are or-
dered by rural availability, allowing ease of comparison
with urban availabilities. The numbers identify individual
medicines. The web appendix Additional file 1: Table S1
lists the medicines, reference numbers and uses. Some
medicines are identified in the text below.
Figure 1 shows that in 2006 urban availability of each
tracer medicine was consistently above or in a few cases
equal to rural availability. The four medicines most
widely available in rural areas (probability > 75%) in 2006
were the then first line anti-malarial treatment (Sulpha-
doxine with Pyramethamine (SP), 38), an anti-amoeba
medicine and an anti-worm treatment (Metronidazole
and Albendazole, 30, 2) and a basic antibiotic (Amoxicil-
lin, 5). For these, the urban/rural gap was also small
(Figure 1). The eleven other medicines with rural avail-
ability >50% included 5 other antibiotics (including a
syrup for children and an injectable); two other anti-
malarials, an injectable and a syrup; Folic acid for
anaemia (22); an anti-inflammatory (Diclofenac, 18);
a treatment for bilharzia (Prazequantel, 37) and a
tranquillizer (Diazepam, 17).
The urban bias evident right across the sample of
tracer medicines in 2006 (Figure 1) persists in the 2009
data (see web appendix Additional file 1: Figure S1), with
some narrowing of the extent urban bias. There were
few differences between in the medicines most widely
available in rural areas in 2006 and 2009. The main shift
is a reduction in availability of SP (38) in 2009 in favourple outlets, 2006: medicines ordered by rural probabilities.
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Lumefantrin (Alu) (6).
The average rural availability in 2006 was 40%, while
the average urban availability was 64%, a difference of 24
percentage points (Table 1). In 2009, this difference had
declined to 18 percentage points (Table 1 row 3). The
last row in Table 1 uses the z-test to test for equality be-
tween the rural and urban probabilities (the null hypoth-
esis). In both years, the null hypothesis is rejected, that
is, the rural and urban probabilities differ significantlyi.
Given the high availability of a few medicines, the low
rural average availability reflects a long tail of essential
medicines largely unavailable in rural but not in urban
areas (Figure 1). The urban bias in medicines availability
is a persistent and serious policy concern.
Absence of urban bias in access to medicines
manufactured in Tanzania
In field research on medicines access in rural Tanzania
in 2006-7, we were surprised to find that a dispropor-
tionate share of medicines actually available in rural
shops and in private and faith-based facilities had been
made in Tanzania [5] p.456. For seven tracer medicines
that were licensed for sale in drug shops in 2006, 66% of
the availability was from Tanzanian producers, while in
the non-governmental health facilities, paediatric sus-
pensions, basic antibiotics, anti-malarials and analgesics
from Tanzanian suppliers were widely stocked.
This finding led to the exploration of the WHO/HAI
data presented here. Figure 2 compares rural and urban
availability for each medicine supplied from Tanzanian
manufacturers. Half of the 40 tracer medicines in this
study were found in the sample outlets in 2006 as prod-
ucts from Tanzanian manufacturers (the number in
2009 was 21). The medicines are ordered in Figure 2 by
rural probability, and as Figure 2 shows, the probability
of finding a Tanzanian manufactured medicine was ap-
proximately equal in rural and in urban outlets. There is
no urban bias.
The data from 2009 confirm this finding (web appen-
dix Additional file 1: Figure S2). While the pattern ofTable 1 Probability of finding a tracer medicine in a sample o
(40 medicines)
Location
2006
Probability Standard error
Rural 0.40 0.0113
Urban 0.64 0.0112
Difference −0.24 0.0159
Two sample test of proportions: z-test = -14.6
H0 : Prural = Purban Pr(|Z| < |z|) = 0.0000
Ha : Prural ≠ Purban Null-hypothesis is rejecturban and rural availability is less closely aligned in 2009
there is no over all urban bias in the availability of
Tanzanian medicines in that year either, and indeed
there is some rural advantage. Note that in 2006, the
probability of finding certain Tanzanian medicines was
quite high: there were 9 such medicines for which the
rural probability in 2006 was >40%. Those probabilities
were lower in 2009: the share of Tanzanian manufac-
tures in total medicines availability appears to have
declined.
Table 2 confirms that there was no significant differ-
ence between the probability of finding a tracer medicine
manufactured in Tanzania in a rural and in an urban out-
let, in 2006 or in 2009. It also confirms the general drop in
availability of Tanzanian medicines in the later year.
Urban bias in availability of imported medicines
Most non-Tanzanian medicines available in the sample
outlets were imported from outside East Africa. There
were 20 medicines for which some supplies were
imported from Kenya, but probabilities were generally
quite low. Just five had availability >25% in 2006: two
anti-malarials (4, 38), a diuretic (24), a tranquilliser (17),
and anti-bacterial eye drops (14). Figure 3 compares
rural and urban availability for each medicine supplied
by Kenyan manufacturers, showing that there is some
urban bias in availability of the Kenyan medicines. This
urban bias persists in 2009 (see web appendix Additional
file 1: Figure S3).
Table 3 confirms this urban bias finding for medicines
manufactured in Kenya. In both years, the probability of
finding a medicine made in Kenya was significantly
lower in rural than in urban areas. The Kenyan medi-
cines were also less available than Tanzanian medicines
over all, in both urban and rural areas, in both years
(compare Tables 2 and 3, rows 2 and 5).
The main source of urban bias in medicines availabil-
ity was however from medicines supplied from manufac-
turers outside Tanzania and Kenya, here called ‘other
imports’. These were mainly sourced from Indian manu-
facturers. ‘Other imports’ were found for every tracerutlet, by rural and urban location, 2006 and 2009
2009
Sample size Probability Standard error Sample size
1880 0.42 0.011 1880
1840 0.60 0.012 1800
−0.18 0.016
z-test = -11.1
Pr(|Z| < |z|) = 0.0000
ed Null-hypothesis is rejected
Figure 2 Probability of finding each medicine in rural and in urban sample outlets 2006: medicines manufactured in Tanzania only,
ordered by rural probabilities.
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rural and urban availability of other imports of each
medicine in 2006. Figure 4 shows consistent urban
bias across the whole set of tracer medicines. Unlike
Tanzanian-manufactured medicines, other imports were
much more likely to be found in urban shops and facil-
ities than in rural outlets. Only three medicines showed
equal urban and rural availability, all with low availabil-
ity: an asthma inhaler (10), a tranquilliser (17) and an
anti-epilepsy medicine (36).
Additional file 1: Figure S4 in the web appendix shows
the equivalent figure for 2009. The urban bias persists
across the sample in 2009, though it appears somewhat
smaller, and there are two medicines (Folic Acid, forTable 2 Probability of finding a tracer medicine manufacture
location, 2006 and 2009 (40 medicines)
Location
2006
Probability Standard error
Rural 0.172 0.0087
Urban 0.163 0.0086
Difference 0.009 0.0122
Two sample test of proportions: z-test = 0.7588
H0 : Prural = Purban Pr(|Z| < |z|) = 0.4480
Ha : Prural ≠ Purban Null-hypothesis is acceptanaemia, important in pregnancy, and Furosemide, a di-
uretic) that have wider rural than urban availability from
other imports in 2009. Table 4 confirms the impression
of a highly significant urban bias in both years: the prob-
ability of finding a medicine imported from outside Tan-
zanian and Kenya in a rural area was very significantly
lower than the urban probability in both 2006 and 2009,
though the bias in 2009 was smaller and rural availability
higher (Table 4).
In summary, the entire rural disadvantage in access to
medicines in Tanzania, relative to the urban access, is
shown in these data sets to be attributable to urban bias
in the distribution of imported medicines – and notably
in non-Kenyan imports that come largely from thed in Tanzania in a sample outlet, by rural and urban
2009
Sample size Probability Standard error Sample size
1880 0.113 0.0073 1880
1840 0.097 0.0070 1800
0.016 0.010
z-test = 1.587
Pr(|Z| < |z|) = 0.112
ed Null-hypothesis is accepted
Figure 3 Probability of finding each medicine in rural and in urban sample outlets 2006: medicines manufactured in Kenya only,
ordered by rural probabilities.
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this is the case right across the sample of medicines: the
average bias is not generated by a few outliers. The
urban bias in access to imports is mitigated only by
equitable rural/urban distribution of Tanzanian-made
medicines.
Finally, we can compare the rural and urban availabil-
ities of two categories of these medicines: those available
as both Tanzanian-manufactured and imported items,
and those available only as imports. Table 5 shows that
in both years, the rural and the urban availability of
these essential medicines was higher for medicines that
were both manufactured in Tanzania and imported as
compared to the subset of medicines available only as
imports. The rural disadvantage in availability of theseTable 3 Probability of finding a medicine manufactured in Ke
and 2009 (40 medicines)
Location
2006
Probability Standard error
Rural 0.052 0.0051
Urban 0.090 0.0067
Difference −0.039 0.0084
Two sample test of proportions: z-test = -4.595
H0 : Prural = Purban Pr(|Z| < |z|) = 0.0000
Ha : Prural ≠ Purban Null-hypothesis is rejectmedicines was particularly severe in relation to medi-
cines available only from imports in both years (Table 5).
It follows that more local production, both of those
medicines already locally produced, and also of medi-
cines currently available solely as imports, may improve
rural availabilities.
Discussion: explaining urban bias
What factors may explain the observed urban bias, and
to what extent can supporting evidence be found in
these data or the relevant literature to support these
explanations?
A first hypothesis may be that the urban bias is a fea-
ture of private market distribution, while public sector
distribution of imported medicines is bias-freej. Thenya in a sample outlet, by rural and urban location, 2006
2009
Sample size Probability Standard error Sample size
1880 0.048 0.0049 1880
1840 0.083 0.0070 1800
0.034 0.0082
z-test = -4.222
Pr(|Z| < |z|) = 0.0000
ed Null-hypothesis is rejected
Figure 4 Probability of finding each medicine in rural and in urban sample outlets 2006: medicines manufactured outside Tanzania
and Kenya only, ordered by rural probabilities.
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ities, and the public facilities source almost all medicines
from the public distributor, the Medical Stores Depart-
ment (MSD) [33]. Therefore this hypothesis can be
tested using these data by examining the extent to which
the availability of medicines in public facilities, sourced
from Tanzanian manufacturers and from imports, dis-
plays urban bias.
As Table 6 shows, the hypothesis is rejected. The
urban bias in availability of other imports of medicines
is highly significant in the public sector, as in the whole
sample in 2006. Additional file 1: Table S2 in the web
appendix shows that this was also the case in 2009. The
unbiased distribution of medicines made in Tanzania is
confirmed for the public sector sub-sample. The prob-
ability of finding a Kenyan medicine in the public sector
outlets is very low in both years, while the urban bias of
the other imports is highly significant in the public sec-
tor sub-sample alone.Table 4 Probability of finding a medicine manufactured outsi
urban location, 2006 and 2009 (40 medicines)
Location
2006
Probability Standard error
Rural 0.163 0.0085
Urban 0.375 0.0113
Difference −0.212 0.014
Two sample test of proportions: z-test = -14.575
H0 : Prural = Purban Pr(|Z| < |z|) = 0.0000
Ha : Prural ≠ Purban Null-hypothesis is rejectA second hypothesis is that, given the reliance on out-
of-pocket spending for access to medicines in all sectors
in Tanzania, and the extensive reliance of the population
on purchase of medicines from shops [33], the urban
bias among imported medicines may result from the
lower purchasing power found in the rural areas. That
is, outlets in rural areas, including public sector and
faith-based facilities, may stock only those medicines
that rural consumers can afford. If the imported medi-
cines are predominantly those in the higher price
bracket, then that might explain the observed tendencies
for the imported medicines to ‘stick’ in urban areas.
Conversely, if the medicines produced in Tanzania are in
the lower price bracket, then that may explain their
more even rural/urban distribution.
Figure 5 shows that in 2006 the medicines manufac-
tured in Tanzania did tend to be in lower price brackets as
compared to the set of all the tracer medicines. The figure
also shows however that some medicines manufactured inde Tanzania or Kenya in a sample outlet, by rural and
2009
Sample size Probability Standard error Sample size
1880 0.251 0.0100 1880
1840 0.412 0.0116 1800
−0.160 0.0160
z-test = -10.324
Pr(|Z| < |z|) = 0.0000
ed Null-hypothesis is rejected
Table 5 Probability of finding a tracer medicine in a sample outlet, by rural and urban location and manufacturing
origin, 2006 and 2009 (40 medicines)
Location 2006 2009
Manufactured in
Tanzania and imported
(20 medicines)
Imported only: not
manufactured in Tanzania
(20 medicines)
Manufactured in Tanzania
and imported (21 medicines)
Imported only: not manufactured
in Tanzania (19 medicines)
Rural 0.53 (0.016) 0.26 (0.014) 0.49 (0.016) 0.34 (0.016)
Urban 0.71 (0.015) 0.56 (0.016) 0.63 (0.016) 0.58 (0.017)
Difference −0.18 (0.022) −0.30 (0.022) −0.14 (0.023) −0.24 (0.023)
Two sample test
of proportions:
z-test = -7.91 z-test = -13.27 z-test = -5.93 z-test = -9.91
H0 : Prural = Purban Pr(|Z| < |z|) = 0.0000 Pr(|Z| < |z|) = 0.0000 Pr(|Z| < |z|) = 0.0000 Pr(|Z| < |z|) = 0.0000
Ha : Prural ≠ Purban Null-hypothesis is rejected Null-hypothesis is rejected Null-hypothesis is rejected Null-hypothesis is rejected
Note: sampling errors in brackets (in italics).
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ple. Furthermore, the price range of medicines produced
in Tanzania was significantly higher in relation to the sam-
ple as a whole in 2009 (see web appendix Additional file 1:
Figure S5). Tanzanian producers sold a range of medi-
cines, including some of the higher priced items, and the
lack of urban bias is consistent across all items.
If it were the case that the more expensive imported
medicines had a larger urban bias than the less expen-
sive items, this would provide partial support for the
view that urban bias in imports is influenced by low
rural purchasing power. Figure 6 is designed to address
this hypothesis. It shows the rural/urban probability gap
for other imports. The medicines are ordered by price
per dose (right hand axis). The lower line on the graph
shows the rural availability of each medicine; the higher
line is the urban availability. The distance between the
two lines – highlighted as a shaded area – shows the
rural/urban probability gap in availability of other im-
ports of each medicine.
As Figure 6 shows, the urban bias in access to other
imports runs right across the price spectrum, though the
larger probability gaps do tend to be at the higher-priced
end. There are just six medicines at the lower price end
showing no or little urban bias, and all with low urbanTable 6 Probability of finding a tracer medicine in a public se
manufacturing origin, 2006 (40 medicines)
Location All medicines Tanzanian medic
Rural 0.34 (0.011) 0.206 (0
Sample size = 640
Urban
Sample size = 600 0.59 (0.011) 0.252 (0
Difference −0.25 (0.0159) −0.045 (0
z-test −8.9 −1.90
H0: Prural = Purban Pr(|Z| < |z|) = 0.0000 Pr(|Z| < |z|) = 0.0
Ha : Prural ≠ Purban Null hypothesis is rejected Null hypothesis is ac
Note: sampling error in brackets (in italics).and rural import availability. Of these, three had high
(over 50%) general rural availability driven by local and
Kenyan production (the then first line anti-malarial, SP
(38), a paediatric antimalarial (4), and a tranquilliser
(17), see Figures 1 and 2). The other three medicines
(antibiotic eye drops (14), and anti-epileptic (36) and an
asthma inhaler (10)) were other-imports-only items, with
general low availability across the whole sample despite
a low price per dose.
The equivalent Additional file 1: Figure S6 for 2009 in
the web appendix shows a similar picture. The urban
bias is slightly lower over all, and it again tends to be
higher for the higher priced medicines, while the avail-
ability of lower priced imported items tends to be quite
low in rural and urban areas. It appears therefore to be
the case that higher priced imports are somewhat more
subject to urban bias than cheaper imported medicines,
perhaps because of lower rural purchasing power. But
this cannot offer a complete explanation of the urban
bias in imports, since some lower priced items also dis-
play bias (Figure 6).
What other likely explanatory factors can be identified
from the literature? Part of the explanation may lie in
the organisation of distribution channels for local manu-
factures and for imports. Global medicines supply chainsctor sample outlet, by rural and urban location and
ines Kenyan medicines Other medicines
.016) 0.005 (0.003) 0.12 (0.013)
.017) 0.038 (0.008) 0.29 (0.018)
.024) −0.034 (0.008) −0.17 (0.022)
−4.13 −7.53
57 Pr(|Z| < |z|) = 0.000 Pr(|Z| < |z|) = 0.0000
cepted Null hypothesis is rejected Null hypothesis is rejected
Figure 5 Median price per dose per medicine 2006: all tracer medicines (panel A) compared to the subset of those medicines both
produced in Tanzania and also imported (panel B).
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risks [37], while local manufacturers such as Shelys,
the largest pharmaceutical producer in Tanzania, have
shorter supply chains when selling into the home mar-
ket. For Tanzania-based manufacturers, the home mar-
ket is generally their core business, and potentially theyFigure 6 Urban-rural probability gap 2006: medicines imported from
of each medicine.have greater market information, and flexibility to re-
spond to market needs. One manufacturer in Tanzania
explainedk that the firm operated its own distribution
network to ensure wide distribution. He also noted that
medicine packets include information in Kiswahili, in-
creasing accessibility and trust for purchasers, smalloutside Tanzania and Kenya, ordered by median price per dose
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the locally produced items – for example, branded ge-
nerics from Shelys such as Sheladon paracetamol – had
brand recognition in shopsl.
There is also some evidence that rural Tanzanian con-
sumers have developed trust in Tanzanian medicines as
compared in Indian competitors. Exit interviews with
medicines purchasers in 69 private and NGO rural med-
icines outlets (shops and facilities) were asked in 2006
about their preferences for country of origin of medi-
cines for three example illnesses; of those who expressed
an opinion, more than half preferred Tanzanian medi-
cines over imports for pneumonia and diarrhoea, while
over a third preferred Tanzanian medicines for malariam.
European medicines came next in terms of preferences,
with Kenyan and Indian medicines trailing well behind.
Conversely many private wholesalers represent indi-
vidual Indian manufacturers, and are known to concen-
trate on urban distribution to facilities and pharmacies.
Interviewees in 2010n confirmed that few Dar es
Salaam-based wholesaler/importers had up-country dis-
tribution networks. Urban consumers are also more
likely to demand imported medicines – in particular,
high-priced European brands – and the importers tend
to concentrate on supplying urban markets [5].
Interviews and recent studies of distribution of subsi-
dised imported anti-malarials in Tanzania confirm that for
importers to distribute widely up-country required the
building of much improved distribution networks. From
2006 Tanzania switched from its previous first line anti-
malarial medicine, Sulphadoxine-Pyrimethamine (SP), to
fixed combination Artemisinin-based medicines (ACTs).
Two pilot experiences of distribution of subsidised
imported ACTs to private shops were undertaken.
One pilot, supported by Management Sciences for
Health (MSH), and US-fundedo, distributed the medi-
cines to licensed drug shops called Accredited Drug
Dispensing Outlets (ADDOs). A wholesaler interviewed
in 2010p described the large amount of travelling and per-
suasion, and adaptation of delivery networks, required to
encourage uptake by rural shopkeepers. Studies of the sec-
ond pilot distribution of ACTS to shops in two districts,
supported by the Clinton Foundation, from 2007 [38,39],
found that the distribution of both ACTS and locally pro-
duced SP was patterned by geography, remoteness being
associated with lower rates of stocking; however the Ken-
yan version of SP was very widely available in the studied
districts, with no difference in stocking by remoteness.
The study notes that the Kenyan medicine was somewhat
cheaper than the Tanzanian competitor, and that the dif-
ferences may also be due to different distribution patterns,
but no evidence was available on the latter issueq.
While the organisation of private distribution net-
works may provide part of the explanation for privatesector urban bias in distribution of imported medicines,
the finding of a similar bias in public sector distribution
remains a puzzle. The Medical Stores Department (MSD),
the public sector medicines distributor, should in principle
be supplying equally to rural and urban facilities, yet
imported medicines were more likely to be found in the
urban than in the rural public sector.
A partial explanation for this finding may lie in the
urban location of large hospitals in Tanzania, since these
are the facilities likely to be using the more complex
medicines that are also likely to be sourced only from
imports. However this does not offer a complete explan-
ation, since urban bias in public sector availability of
imported medicines is observed for most medicines in
this data set, whether import-only or available from both
local manufacturers and importers. Another explanatory
factor may be that urban facilities are more likely than
rural facilities to raise and retain fees which can be used
for medicines purchases to fill gaps in supply. The
sources of public sector urban bias, including the bal-
ance between distribution decisions by the Medical
Stores Department and the outcomes of individual
health facility procurement decisions, deserve further
investigationr.
Finally, a comparison of the 2006 findings, discussed
in detail here, with the 2009 findings in the web appen-
dix shows that the share of Tanzanian-based pharma-
ceutical manufacturers in their local market appears to
be falling. This is a cause for concern, because this arti-
cle’s findings suggest that this trend may increase the
relative disadvantage of the rural population in access to
essential medicines. It will also, of course, reduce indus-
trial employment and development within the country.
The decline may be in part the result of the switch from
local production to imports of first line anti-malarials,
previously a major product for several Tanzanian manu-
facturers, but this is unlikely to be the full explanation.
Conclusion
This article has employed mainly graphical analysis to
demonstrate that the medicines surveys for Tanzania for
2006 and 2009 identify a pattern of urban bias in access
to imported medicines, while confirming that access to
medicines produced in Tanzania does not display urban
bias. The article has also shown that urban bias in
imported medicines generally exists across the full range
of the 40 tracer medicines in the WHO/HAI studies
from which the data are drawn.
The article thus provides prima facie evidence that lo-
cally produced medicines are more accessible than im-
ports for rural consumers, and that medicines which are
both imported and locally produced display greater rural
and urban availability than those which are import-only.
Since the most severe poverty in Tanzania is in rural
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access to medicines in general, this evidence suggests
that building up local production may support improved
rural access to medicines. The local production of medi-
cines appears to be an area of policy with potential syn-
ergies between industrial and health policy objectives.
As the discussion noted, these empirical findings are
new, and they remain largely unexplained in the broader
literature. This article’s findings indicate that further in-
vestigation is required of the reasons for poor rural ac-
cess to medicines, including the different organisation
and performance of distribution channels used by local
producers and by importers, and hence of the better per-
formance of local producers in reaching rural consumers
identified here.
Endnotes
aSource: interviews forming part of unpublished research
in Tanzania by Mackintosh and Mujinja for UNITAID 2010.
bSee http://www.haiweb.org/medicineprices/ for methods,
survey reports and publications from this cross-country data
collection exercise.
cOral rehydration salts (ORS) were included in the
2009 tracer medicines list but not in the 2006 survey; to
allow systematic comparison of the two years, we have
dropped ORS from the data as presented, leaving 40
tracer medicines. The Additional file 1: Table S1 in the
web appendix lists the tracer medicines and their uses.
dA fourth region was included in 2009; this was
dropped from analysis of the 2009 data to allow system-
atic comparison of the two years.
e‘Non-governmental Action to Improve the Access of
the Poor to Good Quality Low Cost Drugs’ 2006-8,
funded by the UK ESRC. See acknowledgements. The
full research report (2009), and project publications, are
available at http://www.esrc.ac.uk/my-esrc/grants/RES-
155-25-0046/read
fUnpublished report to UNITAID by Mackintosh and
Mujinja with Justin-Temu, entitled ‘Interactions between
Global Policy and Local Markets and Production of
Medicines: a case study in Tanzania’ 2011.
gA search for “urban bias” in Pubmed produced 56 ref-
erences, including [40] on NGOs and [41] among many
on health workers; also [42] on HIV treatment; searches
did not find other assessments of the type in this paper
on medicines distribution.
hThe WHO/HAI datasets do not appear to have been
systematically analysed for rural vs. urban disadvantage:
in cross-country and summary publications; this is not a
theme discussed, for example, in [12] or [43,44]; individ-
ual country reports such as [35,36] however do report
this divergence.
iThe last row in Table 1, and in the subsequent tables,
shows the results of the tests for the difference betweentwo proportions under the null-hypothesis that the dif-
ference is zero. The relevant test statistic is the z-test,
based on the normal distribution. The results in Table 1
show the computed value of the z-test statistic and its
probability value.
jThis hypothesis was suggested by a Tanzanian official
at a presentation of an early draft of these findings.
kInterview by Mujinja and Mackintosh 2010.
lUnpublished data from the study cited in footnote e.
mUnpublished data from the study cited in footnote e.
nInterview by Mujinja and Mackintosh 2010.
oSee http://www.msh.org/news-events/news/accredited-
drug-dispensing-outlets-in-tanzania-an-example-of-succes
sful-private
pInterview by Mujinja and Mackintosh 2010.
qSee also [45].
rA referee suggested that different patterns of burden
of disease in urban and rural areas [46] might provide a
further explanation of this finding. These disease burden
differences have been narrowing in Tanzania [46]. How-
ever the fact that our urban bias finding holds across
our whole data set suggests these differences may not be
a key explanatory variable.
Additional file
Additional file 1: Web appendix tables and figures.
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